Effectiveness, safety, and cost-effectiveness of norvancomycin in the management of acute hematogenous osteomyelitis in pediatric patients: A retrospective case study

Xueqin Zhang,Nan Zhang,Yuntao Pei,Ningning Hu,Xiaohui Chen,Liming Zhang,Yile Zhao
DOI: https://doi.org/10.1097/md.0000000000040335
IF: 1.6
2024-11-13
Medicine
Abstract:Acute hematogenous osteomyelitis (AHO) occurs when bacteria invade bone cells and the extracellular matrix, leading to their proliferation. It is typically accompanied by a host inflammatory response, characterized by the onset of symptoms such as fever, local erythema, swelling, and tenderness in the affected bones within 2 weeks. [ 1 ] The disease exhibits an acute onset and rapid progression. Failure to administer timely treatment may result in bone destruction, epiphyseal irritation, adjacent joint infection, and other complications. In severe cases, it can progress into chronic osteomyelitis, leading to bone defects, limb deformities, and sensory disturbances. [ 2 ] Studies have shown that the prevalence of AHO in children has exhibited a significant increase in recent years, particularly in developing countries where the incidence surpasses that observed in developed nations. Moreover, there is a higher prevalence among boys and younger age groups. [ 3 , 4 ]
medicine, general & internal
What problem does this paper attempt to address?